Detalhe da pesquisa
1.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507657
2.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs
; 38(5): 1570-1579, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32140889
3.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Int J Mol Sci
; 18(5)2017 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28481241
4.
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 28(11): 2237-2247, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363301
5.
Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33688022
6.
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Clin Cancer Res
; 25(23): 6976-6985, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31481511
7.
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Neuro Oncol
; 18(8): 1146-56, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26902851
8.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Drug Des Devel Ther
; 9: 4479-99, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26309397
9.
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 16(3): 200-8, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25516338
10.
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J Thorac Oncol
; 10(2): 353-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25611228
11.
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
J Thorac Oncol
; 10(1): 134-42, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25371077
12.
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J Clin Oncol
; 31(34): 4349-57, 2013 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145346
13.
Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 13(5): 340-6, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22266043
14.
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Lung Cancer
; 78(3): 276-81, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23043970
15.
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Clin Lung Cancer
; 10(4): 252-6, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19632943
16.
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
J Clin Oncol
; 27(28): 4787-92, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19720897